Moleculin Biotech, Inc.

MBRX

US60855D3098

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 16/07/2024 BST			5-day change	1st Jan Change
4.25 ^USD	+0.58%		+30.69%	-66.99%

07-10	Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML	CI
06-14	Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial	CI

Moleculin Biotech, Inc. Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor

January 10, 2018 at 01:30 pm

Moleculin Biotech, Inc. announced it has expanded the company's development pipeline for the treatment of acute myeloid leukemia ("AML") with an immuno-stimulating STAT3 inhibitor.

Latest news about Moleculin Biotech, Inc.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML	07-10	CI
Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial	06-14	CI
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)	05-15	CI
Transcript : Moleculin Biotech, Inc., Q1 2024 Earnings Call, May 13, 2024	05-13
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Transcript : Moleculin Biotech, Inc. - Special Call	05-07
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data	05-07	CI
Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman	05-01	CI
Transcript : Moleculin Biotech, Inc. - Special Call	04-24
Sector Update: Health Care Stocks Ease in Afternoon Trading	04-18	MT
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU	04-18	MT
Top Premarket Decliners	04-16	MT
Transcript : Moleculin Biotech, Inc. - Special Call	03-28
Sector Update: Health Care Stocks Advance Late Afternoon	03-27	MT
Sector Update: Health Care	03-27	MT
Moleculin Biotech Shares Rise Following Patent Announcement	03-27	MT
Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating	03-26	MT
Transcript : Moleculin Biotech, Inc., 2023 Earnings Call, Mar 25, 2024	03-25
Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial	03-25	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
North American Morning Briefing : Markets on Hold as Fed Decision Nears	03-20	DJ
Moleculin Biotech to Effect 1-For-15 Reverse Stock Split to Regain Compliance	03-19	MT
Transcript : Moleculin Biotech, Inc. - Special Call	02-28
Transcript : Moleculin Biotech, Inc. - Special Call	02-14
Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3	01-24	CI

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.25 USD

Average target price

30 USD

Spread / Average Target

+605.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECULIN BIOTECH, INC.	-66.99%	9.77M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs